Amphotericin B

**Indication**
Blastomycosis  
**ICD11 code:** 1F22

**INN**
Amphotericin B

**Medicine type**
Chemical agent

**List type**
Core

**Formulations**
Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate)

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2013 (TRS 985)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Wikipedia**
Amphotericin B

**DrugBank**
Amphotericin b

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.